Supplemental Table 1 Antidepressant use of cohort members in the year prior to cohort entry by the entry-defining Supplemental Table 3 Cardiovascular co-morbidity of cohort members in the year prior to cohort entry by cohort entry- Results are expressed as Number (%) *Severe CHF is defined by the presence of a diagnosis for decompensated CHF or by any CHF diagnosis followed by a prescription of a loop diuretic within 3 months.
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Supplemental Table 4 Non Supplemental Table 7 Crude and adjusted odds ratios of sudden cardiac death or near-death associated with current use of venlafaxine relative to current fluoxetine, citalopram and dosulepin use using the criterion of a minimum 10% change in odds ratio to keep covariates for adjustment Past user and non-user are included in the model Covariates kept for adjustment: alcohol abuse, diabetes, benzodiazepine, drugs with stronger evidence of prolonging QT, loop diuretics, all in the year prior to the year before index date, AMI in the 3 months before index date.
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Supplemental Table 8 Crude and adjusted odds ratios of sudden cardiac death or near-death associated with current use of venlafaxine relative to current Past user and non-user are included in the model *Adjusted for BMI ≥ 30, smoking status, alcohol abuse, depression severity, suicide attempt, diabetes, CABG & endosc CA procedures, supraventricular arrhythmias, Left ventricular hypertrophy, CAD and angina, CHF, severe CHF, ischaemic stroke, TIA, peripheral vascular disease, hyperlipidaemia, hypertension, hypokalemia, hypokalaemia, rheumatoid arthritis, epilepsy, schizophrenia, use of anti psychotics, benzodiazepine, mood stabilizer, anti-arrhythmics, drugs with some evidence of prolonging QT, drugs with stronger evidence of prolonging QT, lipid regulating drugs, loop diuretics all in the year prior to the year before index date and AMI in the year prior index date.
